Could it be18 Apr 2021 11:07
AvidiMab that comes into play with what is coming from continuum.....
'The team now plan to isolate antibodies from the exceptional survivors, clone them in the lab, and use these monoclonal antibodies, to treat pancreatic cancer patients otherwise destined to die of the disease. These antibodies will be cloned from Continuum patients, in collaboration with Prof Gavin Screaton who has pioneered the use of patient-derived monoclonal antibodies to treat viral infections. This will be one of the first attempts to exploit monoclonal antibody treatment, which is of proven use in viruses, and extend it to treat pancreatic cancer.
Pancreatic cancer is often described as an “immune desert” and the “toughest nut to crack” in the field of immunotherapy in cancer. Monoclonal antibodies are the most important advance in cancer therapy in the last 20 years. In particular, the Nobel prize-winning monoclonal antibodies known as checkpoint inhibitors have transformed the prospects of patients with many cancers, malignant melanoma being a prime example.
Unfortunately, checkpoint inhibitors have no benefit in pancreatic cancer. The Oxford group of investigators and Continuum believe that patients who survive metastatic pancreatic cancer are the “extreme phenotypes” who demonstrate that even the most lethal disease can be controlled by an appropriate immune response.
Making patient-derived monoclonal antibodies from them is exploiting this immune response for the benefit of others. Antibodies have an anti-tumour effect in their own right, but perhaps more importantly, direct other arms of the immune response, such as T cells and natural killer cells to target and attack the tumour. Because monoclonal antibodies are already widely used in clinical practice, this approach provides an opportunity to translate an experimental approach into a medicine to crack the toughest nut of all: pancreatic cancer.'
Sign In
Follow the stocks
